Refine by
Limb Ischemia Articles & Analysis
26 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
This is core to Amsel's mission - saving limbs and saving lives for both those who serve, and to serve the broader public's need for improved trauma care." ...
Engineered to fulfill an unmet clinical need in treating patients suffering from Critical Limb Ischemia (CLI), the Temporary Spur Stent System consists of a unique, retrievable nitinol stent system with radially expandable spikes or “spurs” designed to create channels for increased uptake of antiproliferative drugs (“limus” based) into the ...
It´s the first trial to demonstrate the benefits of dual pathway inhibition - with the anticoagulant Xarelto in combination with the antiplatelet aspirin - in these PAD patients at high risk of major adverse cardiovascular events (MACE) and especially major adverse limb events (MALE). "This approval is an important advance for patients with PAD in Japan," said Dr. ...
ByBayer AG
Thomas Rand, MD from the Klinik Floridsdorf Vienna, Austria presented the initial clinical results from the safety and performance study of REVA’s MOTIV sirolimus-eluting bioresorbable scaffold in patients with Critical Limb Ischemia (CLI) and BTK lesions. Prof. Rand presented the study at the Leipzig Interventional Course (LINC) 2022. ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a ...
Isa Rizk, CEO and Co-Founder of Reflow Medical, continues, “We are setting a new standard in the design and engineering of effective technology used to treat complex cardiovascular disease including critical limb ischemia. Our comprehensive portfolio of support catheters, microcatheters, CTO devices, and future therapeutic devices (Spur) helps expand our ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a ...
He is recognized as a Key Opinion Leader on the diabetic foot, lower extremity wound care, limb salvage, podiatric medicine, and surgery. Chief Strategy Officer – Douglas W.F. ...
ACP-01 is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis in the heart and limbs of individuals who suffer from ischemia, and cell transplants from human islets or stem cells, hold huge promise in the treatment of diabetes. ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of ...
” He continued, “This product line was advance-engineered for treating complex critical limb ischemia (CLI), targeting an unmet clinical need.” Along with other physician partners, Dr. ...
The device was developed in response to unmet clinical needs in treating patients suffering from critical limb ischemia (CLI), a serious condition in below-the-knee (BTK) disease that can result in high rates of restenosis and further treatment challenges. ...